Evidence map›Paper›PMID 38293095›Full record

ArticlebioRxiv : the preprint server for biology2025

Genome scale CRISPR screens identify actin capping proteins as key modulators of therapeutic responses to radiation and immunotherapy.

Shan Xin, Paul A Renauer, Chuanpeng Dong, Yanzhi Feng, Ping Ren, Qianqian Lin, Feifei Zhang, Narges Tafreshi, Peter M Glazer, Sidi Chen and 1 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Shan XinDepartment of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA.
Paul A RenauerDepartment of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA.
Chuanpeng DongDepartment of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA.
Yanzhi FengDepartment of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA.
Ping RenDepartment of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA.
Qianqian LinDepartment of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA.
Feifei ZhangDepartment of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA.
Narges TafreshiCellinfinity Bio, New Haven, Connecticut, USA.
Peter M GlazerDepartment of Therapeutic Radiology, Yale University, New Haven, Connecticut, USA.
Sidi ChenDepartment of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA.
Nipun VermaDepartment of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA.
Yale University · USYale Cancer Center · US

Funding

PREDOCTORAL TRAINING PROGRAM IN GENETICST32GM007499 · NIGMS · YALE UNIVERSITY · PI CARLSON, JOHN R, REINKE, VALERIE J · 1985 to 2022
$13.9M
Targeting DNA Repair for Cancer Therapy.R35CA197574 · NCI · YALE UNIVERSITY · PI PETER M GLAZER · 2017 to 2026
$8.6M
Oncometabolites, DNA Repair, and CancerR01ES005775 · NIEHS · YALE UNIVERSITY · PI PETER M GLAZER · 1998 to 2026
$8.0M
Yale Cancer Biology Training GrantT32CA193200 · NCI · YALE UNIVERSITY · PI PETER M GLAZER, Qin Yan · 2016 to 2026
$3.6M
(PQ4) Novel tools for in vivo study of genetic interactions in cancer progressionR01CA231112 · NCI · YALE UNIVERSITY · PI CHEN, SIDI · 2018 to 2022
$3.0M
High-throughput in vivo genetics for immunotherapy target discoveryDP2CA238295 · NCI · YALE UNIVERSITY · PI CHEN, SIDI · 2018 to 2018
$2.5M
Advanced development of composite gene delivery and CAR engineering systemsR33CA281702 · NCI · YALE UNIVERSITY · PI CHEN, SIDI · 2023 to 2025
$1.2M
NCI NIH HHS DP2 CA238295NCI NIH HHS R01 CA231112NCI NIH HHS R33 CA281702NCI NIH HHS R35 CA197574NCI NIH HHS T32 CA193200NIEHS NIH HHS R01 ES005775NIGMS NIH HHS T32 GM007499
6 · The paper itself

Abstract

Radiotherapy (RT), is a fundamental treatment for malignant tumors and is used in over half of cancer patients. As radiation can promote anti-tumor immune effects, a promising therapeutic strategy is to combine radiation with immune checkpoint inhibitors (ICIs). However, the genetic determinants that impact therapeutic response in the context of combination therapy with radiation and ICI have not been systematically investigated. To unbiasedly identify the tumor intrinsic genetic factors governing such responses, we performed a set of genome-scale CRISPR screens in melanoma cells for cancer survival in response to low-dose genotoxic radiation treatment, in the context of CD8 T cell co-culture and with anti-PD1 checkpoint blockade antibody. Two actin capping proteins,

Identifiers

PMID38293095
PMCPMC10827061
OpenAlexW4390917713

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.